ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bristol-Myers Plans Amylin Site Closure

by Michael McCoy
April 8, 2013 | APPEARED IN VOLUME 91, ISSUE 14

Eight months after completing its acquisition of the diabetes drug firm Amylin Pharmaceuticals, Bristol-Myers Squibb is closing the company’s San Diego headquarters. The facility employs about 420 people in R&D, manufacturing, commercial, and administrative roles. Some employees will be offered opportunities to relocate to other facilities, BMS says. The closure is the second recently by a big pharma firm in San Diego. In February, Pfizer shuttered its CovX research unit, which focused on peptide therapeutics development.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment